Show simple item record

dc.contributor.authorDean, Emma J
dc.contributor.authorBanerji, U
dc.contributor.authorSchellens, J
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorJimenez, B
dc.contributor.authorvan Brummelen, E
dc.contributor.authorBailey, C
dc.contributor.authorCasson, E
dc.contributor.authorCripps, D
dc.contributor.authorCullberg, M
dc.contributor.authorEvans, S
dc.contributor.authorFoxley, A
dc.contributor.authorLindemann, J
dc.contributor.authorRugman, P
dc.contributor.authorTaylor, N
dc.contributor.authorTurner, G
dc.contributor.authorYates, J
dc.contributor.authorLawrence, P
dc.date.accessioned2018-04-24T19:57:12Z
dc.date.available2018-04-24T19:57:12Z
dc.date.issued2018-03-14
dc.identifier.citationA phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. 2018, Cancer Chemother Pharmacolen
dc.identifier.issn1432-0843
dc.identifier.pmid29541803
dc.identifier.doi10.1007/s00280-018-3558-z
dc.identifier.urihttp://hdl.handle.net/10541/620904
dc.description.abstractAZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer chemotherapy and pharmacologyen
dc.titleA phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, The University of Manchester, Manchester, UKen
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
refterms.dateFOA2018-12-17T15:19:41Z
html.description.abstractAZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) and the effect of food (Part B) on the PK/safety of the tablet.


Files in this item

Thumbnail
Name:
s00280-018-3558-z.pdf
Size:
823.6Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record